Physician profile
Pselane A Coney
NPI 1558660043
$3,048.47
in general payments reported to CMS, 2019-2025
22 companies · $1,940 in 2025
The $1,940 reported for 2025 was more than what 96% of Acute Care (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $28.96 · 2023: $502 · 2024: $578 · 2025: $1,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932 · Long Term Medical Supply Or Device Loan: $897 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,932.24 |
| Long Term Medical Supply Or Device Loan | $897.30 |
| Education | $189.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,039.96 | 2025 | |
| Janssen Biotech, INC. | $662.57 | 2023-2025 | Tecvayli, Carvykti, Rybrevant |
| Astellas Pharma US INC | $200.58 | 2023-2024 | Cresemba |
| Celgene Corporation | $168.41 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $127.14 | 2022-2023 | |
| Kite Pharma, INC. | $121.91 | 2023-2025 | Yescarta |
| Amgen INC. | $118.42 | 2024 | Blincyto |
| Astrazeneca Pharmaceuticals Lp | $68.88 | 2025 | Enhertu |
| Tempus Ai, INC | $66.50 | 2025 | Xt Cdx |
| Lilly USA, LLC | $59.49 | 2025 | Verzenio, Jaypirca |
| Servier Pharmaceuticals LLC | $56.33 | 2023 | |
| Seagen INC. | $49.99 | 2025 | |
| Caris Mpi, INC. | $46.28 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $44.50 | 2023-2025 | |
| Legend Biotech USA INC. | $36.05 | 2025 | Carvykti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $35.42 | 2025 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.71 | 2025 | |
| Immunocore Limited | $28.33 | 2025 | Kimmtrak |
| Daiichi Sankyo INC. | $26.84 | 2025 | Datroway |
| Regeneron Pharmaceuticals, INC. | $24.92 | 2025 | Lynozyfic |
| Eisai INC. | $16.39 | 2025 | |
| Merck Sharp & Dohme LLC | $15.85 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pselane Coney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.